Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 37.9% on Friday . The stock traded as high as C$0.24 and last traded at C$0.20. Approximately 1,160,600 shares traded hands during trading, an increase of 120% from the average daily volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The company has a market capitalization of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The firm has a 50-day moving average price of C$0.09 and a two-hundred day moving average price of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Basic Materials Stocks Investing
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Investing In Automotive Stocks
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to trade using analyst ratings
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
